Gerard L. Brien

This study shows SS18-SSX sustains oncogenic transcription without needing SWI/SNF activity, identifies P300 as a critical co-factor, and demonstrates targeting P300 or SWI/SNF as therapeutic strategies.

This study identifies AEBP2 as a therapeutic target in EZH2-mutant lymphoma by showing its role in maintaining H3K27me2 levels through a PRC2.2 complex.

This study identifies SUMO2 as a selective vulnerability in synovial sarcoma, showing that SUMO2 inhibition reverses SS18-SSX-driven gene expression and impairs tumor growth.

The paper identifies specific cPRC1 complexes, CBX4/PCGF4, that mediate oncogenic gene repression in DMG cells downstream of H3K27M mutation.